Study Links SABR to Higher 3‑Year Mortality Than Surgery in Early NSCLC

The briefing

An emulated target trial found higher 3‑year all‑cause mortality with SABR versus surgery in early-stage NSCLC (30.3% vs 21.6%). The mortality gap narrowed among patients aged 80 and older.